Market Closed -
Nasdaq
01:30:00 02/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.617
USD
|
-0.47%
|
|
+0.49%
|
-64.74%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
148.4
|
635.7
|
469.5
|
53.48
|
59.93
|
21.36
|
-
|
Enterprise Value (EV)
1 |
148.4
|
635.7
|
469.5
|
53.48
|
59.93
|
21.36
|
21.36
|
P/E ratio
|
-4.41
x
|
-15.6
x
|
-5.83
x
|
-0.46
x
|
-0.57
x
|
-0.28
x
|
-0.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
44.1
x
|
108
x
|
39.7
x
|
3.68
x
|
3.92
x
|
1.27
x
|
1.04
x
|
EV / Revenue
|
44.1
x
|
108
x
|
39.7
x
|
3.68
x
|
3.92
x
|
1.27
x
|
1.04
x
|
EV / EBITDA
|
-8.47
x
|
-18.3
x
|
-6.15
x
|
-0.46
x
|
-0.59
x
|
-0.31
x
|
-0.33
x
|
EV / FCF
|
-
|
-2,08,29,403
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
11,964
|
19,595
|
29,717
|
30,215
|
34,243
|
34,623
|
-
|
Reference price
2 |
12.40
|
32.44
|
15.80
|
1.770
|
1.750
|
0.6170
|
0.6170
|
Announcement Date
|
11/03/20
|
04/03/21
|
01/03/22
|
02/03/23
|
29/02/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
3.364
|
5.885
|
11.84
|
14.52
|
15.3
|
16.83
|
20.63
|
EBITDA
1 |
-17.52
|
-34.8
|
-76.4
|
-116.5
|
-101.9
|
-68.55
|
-63.95
|
EBIT
1 |
-17.6
|
-35.29
|
-77.4
|
-118.2
|
-103.7
|
-79.13
|
-74.34
|
Operating Margin
|
-523.34%
|
-599.64%
|
-653.81%
|
-813.92%
|
-678.21%
|
-470.29%
|
-360.32%
|
Earnings before Tax (EBT)
1 |
-
|
-35.25
|
-78.34
|
-116.7
|
-100.9
|
-77.34
|
-74.75
|
Net income
1 |
-19.69
|
-35.25
|
-78.34
|
-116.7
|
-100.9
|
-77.26
|
-73.24
|
Net margin
|
-585.29%
|
-598.96%
|
-661.72%
|
-803.71%
|
-659.57%
|
-459.18%
|
-354.99%
|
EPS
2 |
-2.810
|
-2.080
|
-2.710
|
-3.880
|
-3.090
|
-2.213
|
-2.053
|
Free Cash Flow
|
-
|
-30.52
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-518.57%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/20
|
04/03/21
|
01/03/22
|
02/03/23
|
29/02/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
3.03
|
3.165
|
3.718
|
4.233
|
3.573
|
2.994
|
3.477
|
3.98
|
3.915
|
3.924
|
3.925
|
4.165
|
4.304
|
4.465
|
4.602
|
EBITDA
1 |
-20.07
|
-26.02
|
-29.82
|
-29.44
|
-28.84
|
-28.43
|
-31.58
|
-31.66
|
-19.36
|
-19.31
|
-20.4
|
-18.3
|
-18.2
|
-18.2
|
-17.7
|
EBIT
1 |
-20.32
|
-26.36
|
-30.19
|
-29.83
|
-29.26
|
-28.88
|
-32.04
|
-32.13
|
-19.81
|
-19.75
|
-20.7
|
-19.43
|
-19.48
|
-19.52
|
-19.23
|
Operating Margin
|
-670.59%
|
-832.83%
|
-812.02%
|
-704.8%
|
-818.95%
|
-964.56%
|
-921.63%
|
-807.34%
|
-506%
|
-503.36%
|
-527.45%
|
-466.43%
|
-452.55%
|
-437.21%
|
-417.85%
|
Earnings before Tax (EBT)
1 |
-20.11
|
-26.05
|
-30.11
|
-29.58
|
-28.77
|
-28.22
|
-31.27
|
-31.36
|
-19.16
|
-19.09
|
-20.05
|
-19.04
|
-19.06
|
-19.18
|
-19.13
|
Net income
1 |
-20.11
|
-26.05
|
-30.11
|
-29.58
|
-28.77
|
-28.22
|
-31.27
|
-31.36
|
-19.16
|
-19.09
|
-20.17
|
-18.96
|
-19.01
|
-19.09
|
-19.13
|
Net margin
|
-663.76%
|
-823.16%
|
-809.79%
|
-698.8%
|
-805.26%
|
-942.65%
|
-899.34%
|
-788.02%
|
-489.5%
|
-486.52%
|
-513.86%
|
-455.22%
|
-441.7%
|
-427.5%
|
-415.67%
|
EPS
2 |
-0.6800
|
-0.8800
|
-1.010
|
-0.9900
|
-0.9600
|
-0.9300
|
-1.020
|
-0.9900
|
-0.5700
|
-0.5400
|
-0.5833
|
-0.5433
|
-0.5400
|
-0.5400
|
-0.5350
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/21
|
01/03/22
|
03/05/22
|
08/08/22
|
03/11/22
|
02/03/23
|
04/05/23
|
03/08/23
|
02/11/23
|
29/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-30.5
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
1.83
|
2.72
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
31.16%
|
22.98%
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/20
|
04/03/21
|
01/03/22
|
02/03/23
|
29/02/24
|
-
|
-
|
Last Close Price
0.617
USD Average target price
2.043
USD Spread / Average Target +231.17% Consensus |
1st Jan change
|
Capi.
|
---|
| -64.74% | 21.36M | | -1.44% | 12.62B | | -9.59% | 7.67B | | +2.04% | 5.41B | | +0.02% | 4.57B | | -51.89% | 3.22B | | +6.42% | 2.59B | | -12.79% | 2.05B | | -8.29% | 1.79B | | +1.67% | 1.76B |
Diagnostic & Testing Substances
|